Acadian Asset Management’s Dermata Therapeutics DRMA Stock Holding History

Acadian Asset Management’s Portfolio DRMA Stock Details DRMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-128	Closed	-$3K	–	2137
2024 Q2	$3K	Hold	128	–	–	﹤0.01%	1719
2024 Q1	$7K	Sell	128 -240	-65%	-$16.5K	﹤0.01%	1523
2023 Q4	$32K	Sell	368 -136	-27%	-$14.7K	﹤0.01%	1521
2023 Q3	$79K	Buy	504 +129	+34%	+$24.7K	﹤0.01%	1352
2023 Q2	$92K	Buy	+375	New	+$102K	﹤0.01%	1422

Other funds holding DRMA

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Acadian Asset Management's DRMA Position: Q3 2024 in Review

Acadian Asset Management sold out of Dermata Therapeutics (DRMA) in Q3 2024, closing a stake of 128 shares — an estimated $3K sold.

Acadian Asset Management first reported a position in DRMA in Q2 2023 and held it in 5 quarters. The position peaked at $92K in Q2 2023. 4 funds tracked by Wall St. Rank hold DRMA as of Q3 2024.

Acadian Asset Management reported no remaining Dermata Therapeutics position as of Q3 2024 after selling out during the quarter.
Acadian Asset Management sold 128 Dermata Therapeutics shares in Q3 2024, an estimated $3K.
Acadian Asset Management first reported a position in Dermata Therapeutics in Q2 2023 and held it in 5 quarters.
Acadian Asset Management's Dermata Therapeutics position peaked at $92K in Q2 2023.
4 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q3 2024.

Based on Acadian Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.